Clinical pharmacology of sodium cellulose phosphate

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The safety and effectiveness of sodium cellulose phosphate (SCP) in the treatment of calcium urolithiasis of absorptive hypercalciuria was explored. Eighteen patients with absorptive hypercalciuria with intestinal hyperabsorption of calcium, normal or suppressed parathyroid function, and active stone disease received 10 to 15 g SCP daily (2.5 to 5 g with meals) and 2 to 3 g magnesium gluconate daily (1 to 1.5 g twice daily orally separately from SCP) for 8 to 54 months, while maintained on a moderate calcium and oxalate restriction. During treatment, serum calcium, immunoreactive parathyroid hormone, and urinary cyclic AMP remained within the normal range. Serum alkaline phosphatase and bone density (measured by photon absorptiometry) did not change significantly or remained within normal limits. Serum concentrations of magnesium, copper, zinc, and iron and blood hematocrit were not significantly altered by therapy. However, urinary calcium returned toward normal, and incidence of renal stone formation markedly decreased. The results suggest that SCP is a safe and an effective drug for absorptive hypercalciuria.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalJournal of Clinical Pharmacology
Volume19
Issue number8-9 I
StatePublished - 1979

Fingerprint

Clinical Pharmacology
Hypercalciuria
Calcium
Serum
Calcium Oxalate
Urolithiasis
Photon Absorptiometry
Parathyroid Hormone
Hematocrit
Cyclic AMP
Bone Density
Magnesium
Alkaline Phosphatase
Meals
Zinc
Copper
Reference Values
Therapeutics
Iron
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical pharmacology of sodium cellulose phosphate. / Pak, C. Y C.

In: Journal of Clinical Pharmacology, Vol. 19, No. 8-9 I, 1979, p. 451-457.

Research output: Contribution to journalArticle

@article{a9316006f90d4a5192ebe30e6752ff1d,
title = "Clinical pharmacology of sodium cellulose phosphate",
abstract = "The safety and effectiveness of sodium cellulose phosphate (SCP) in the treatment of calcium urolithiasis of absorptive hypercalciuria was explored. Eighteen patients with absorptive hypercalciuria with intestinal hyperabsorption of calcium, normal or suppressed parathyroid function, and active stone disease received 10 to 15 g SCP daily (2.5 to 5 g with meals) and 2 to 3 g magnesium gluconate daily (1 to 1.5 g twice daily orally separately from SCP) for 8 to 54 months, while maintained on a moderate calcium and oxalate restriction. During treatment, serum calcium, immunoreactive parathyroid hormone, and urinary cyclic AMP remained within the normal range. Serum alkaline phosphatase and bone density (measured by photon absorptiometry) did not change significantly or remained within normal limits. Serum concentrations of magnesium, copper, zinc, and iron and blood hematocrit were not significantly altered by therapy. However, urinary calcium returned toward normal, and incidence of renal stone formation markedly decreased. The results suggest that SCP is a safe and an effective drug for absorptive hypercalciuria.",
author = "Pak, {C. Y C}",
year = "1979",
language = "English (US)",
volume = "19",
pages = "451--457",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8-9 I",

}

TY - JOUR

T1 - Clinical pharmacology of sodium cellulose phosphate

AU - Pak, C. Y C

PY - 1979

Y1 - 1979

N2 - The safety and effectiveness of sodium cellulose phosphate (SCP) in the treatment of calcium urolithiasis of absorptive hypercalciuria was explored. Eighteen patients with absorptive hypercalciuria with intestinal hyperabsorption of calcium, normal or suppressed parathyroid function, and active stone disease received 10 to 15 g SCP daily (2.5 to 5 g with meals) and 2 to 3 g magnesium gluconate daily (1 to 1.5 g twice daily orally separately from SCP) for 8 to 54 months, while maintained on a moderate calcium and oxalate restriction. During treatment, serum calcium, immunoreactive parathyroid hormone, and urinary cyclic AMP remained within the normal range. Serum alkaline phosphatase and bone density (measured by photon absorptiometry) did not change significantly or remained within normal limits. Serum concentrations of magnesium, copper, zinc, and iron and blood hematocrit were not significantly altered by therapy. However, urinary calcium returned toward normal, and incidence of renal stone formation markedly decreased. The results suggest that SCP is a safe and an effective drug for absorptive hypercalciuria.

AB - The safety and effectiveness of sodium cellulose phosphate (SCP) in the treatment of calcium urolithiasis of absorptive hypercalciuria was explored. Eighteen patients with absorptive hypercalciuria with intestinal hyperabsorption of calcium, normal or suppressed parathyroid function, and active stone disease received 10 to 15 g SCP daily (2.5 to 5 g with meals) and 2 to 3 g magnesium gluconate daily (1 to 1.5 g twice daily orally separately from SCP) for 8 to 54 months, while maintained on a moderate calcium and oxalate restriction. During treatment, serum calcium, immunoreactive parathyroid hormone, and urinary cyclic AMP remained within the normal range. Serum alkaline phosphatase and bone density (measured by photon absorptiometry) did not change significantly or remained within normal limits. Serum concentrations of magnesium, copper, zinc, and iron and blood hematocrit were not significantly altered by therapy. However, urinary calcium returned toward normal, and incidence of renal stone formation markedly decreased. The results suggest that SCP is a safe and an effective drug for absorptive hypercalciuria.

UR - http://www.scopus.com/inward/record.url?scp=0018701499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018701499&partnerID=8YFLogxK

M3 - Article

C2 - 489764

AN - SCOPUS:0018701499

VL - 19

SP - 451

EP - 457

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8-9 I

ER -